Molecular Instruments, Inc.

Los Angeles, CA · Medtech · Private

Hybridization Chain Reaction (HCR) technology platform for multiplexed quantitative RNA and protein imaging in tissue samples

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · molecularinstruments.com

Sector: Medtech
Headquarters: Los Angeles, CA
Total capital: $3.8M

Federal grants: $3.8M; 7 awards · 2021–2025; Rank in peer group#57 of 112
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 1; 6 pending · first 2025; Rank in peer group#34 of 112

Capital timeline

Latest events

Sep 2025Federal grantHealth and Human S · Phase I · Advancing Probe Technology for Ultrasensitive RNA Imaging via Hybridization Chain Reaction$307K
Aug 2025Federal grantHealth and Human S · Phase II · Hybridization Chain Reaction: Automated Ultrasensitive Multiplex RNA and Protein Imaging$710K
Jul 2025Federal grantHealth and Human S · Phase II · Hybridization Chain Reaction: Automated Ultrasensitive Multiplex RNA and Protein Imaging$194K
Aug 2024Federal grantHealth and Human S · Phase II · Hybridization Chain Reaction: Automated Ultrasensitive Multiplex RNA and Protein Imaging$906K
Nov 2022Federal grantHealth and Human S · Phase II · Hybridization Chain Reaction: Highly Multiplexed Quantitative RNA and Protein Imaging$500K
Dec 2021Federal grantHealth and Human S · Phase II · Hybridization Chain Reaction: Highly Multiplexed Quantitative RNA and Protein Imaging$1M
Apr 2021Federal grantHealth and Human S · Phase II · Hybridization Chain Reaction: Highly Multiplexed Quantitative RNA and Protein Imaging$150K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 112 peers

Line = median

Medtech · Instrument

Federal grantsBelow median
Granted patents#34 · top 30%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 7

Jun 5, 2025PendingUltrasensitive Molecular Detection Via Hybridization Chain ReactionUSPTOApplication 19055411
Apr 22, 2025GrantedUltrasensitive Molecular Detection Via Hybridization Chain ReactionUSPTOUS 12,281,352
Oct 10, 2024PendingUltrasensitive Molecular Detection Via Hybridization Chain ReactionUSPTOApplication 18625726

Show all 7 patent records

Ultrasensitive Molecular Detection Via Hybridization Chain ReactionJun 5, 2025 · Application 19055411Pending
Ultrasensitive Molecular Detection Via Hybridization Chain ReactionApr 22, 2025 · US 12,281,352Granted
Ultrasensitive Molecular Detection Via Hybridization Chain ReactionOct 10, 2024 · Application 18625726Pending
Analysis Of Target Molecules Within A Sample Via Hybridization Chain ReactionJun 22, 2023 · Application 17682336Pending
Analysis Of Target Molecules Within A Sample Via Hybridization Chain ReactionSep 8, 2022 · Application 17637253Pending
Analysis Of Target Molecules Within A Sample Via Hybridization Chain ReactionApplication PCTUS2021020919Pending
Analysis Of Target Molecules Within A Sample Via Hybridization Chain ReactionApplication 62986436Pending

GREEN TECHNOLOGIES, INC.Similar federal contract value in Medtech · null in contracts
Precision NeuroscopicsSimilar federal contract value in Medtech · null in contracts
EYENEXO LLCSimilar federal contract value in Medtech · null in contracts
CAMBRIDGE POLYMER GROUP INCSimilar federal contract value in Medtech · null in contracts
AMERICAN BIOOPTICS, LLCSimilar federal contract value in Medtech · null in contracts
Revive Biotechnology Inc.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.